Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified March 2010
Condition: Hepatitis C Recurrence
Intervention: Drug: Nitazoxanide
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Conditions: Bone Marrow; Bone Marrow Stromal Cells; Mesenchymal Stem Cells; Blood Donors
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: Ortho Tri-Cyclen®; Drug: BMS-650032
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified February 2010
Condition: Hepatitis C Virus Infection
Intervention: Drug: CTS-1027, Pegylated Interferon, Ribavirin
Sponsor: Conatus Pharmaceuticals Inc.
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Intervention: Drug: TMC435
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Hepatitis C
Interventions: Drug: telaprevir; Drug: telaprevir; Drug: cyclosporine; Drug: cyclosporine; Drug: tacrolimus; Drug: tacrolimus
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Conditions: Chronic Hepatitis C; Oxidative Stress
Interventions: Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)
Sponsors: The University of North Carolina, Chapel Hill; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health (NIH)
Recruiting - verified February 2010
Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Condition: Hepatitis C
Interventions: Drug: Midazolam; Drug: BMS-791325
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Conditions: Hepatitis C; Thrombocytopaenia
Intervention: Drug: Eltrombopag
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: Ortho Tri-Cyclen®
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Conditions: HIV Infections; Hepatitis C; HCV Infection
Interventions: Drug: PEG2b plus ribavirin followed by placebo; Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Chronic Hepatitis C Infection (HCV)
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (Peg-IFN); Drug: Comparator: Ribavirin (RBV)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Condition: Hepatitis C
Intervention:
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Conditions: Liver Fibrosis; Hepatitis C Virus
Intervention: Procedure: Comparator: Magnetic Resonance Elastography (MRE)
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Hepatitis C
Intervention: Procedure: Comparator: Fine needle aspiration biopsy
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Hepatitis C; Hepatitis C Virus
Interventions: Drug: Fluvastatin; Drug: Peginterferon alfa2a; Drug: ribavirin
Sponsor: University of Chicago
Recruiting - verified February 2010
Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Liver Cancer; Hepatitis B; Hepatitis C
Intervention:
Sponsor: Stanford University
Recruiting - verified February 2010
Conditions: Liver Cancer; Hepatitis B; Hepatitis C
Intervention:
Sponsor: Stanford University
Recruiting - verified February 2010
Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsor: Cangene Corporation
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: PF-00868554; Drug: PF-00868554; Drug: PF-00868554; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2009
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention:
Sponsors: Rockefeller University; New York Presbyterian Hospital
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir; Drug: Tenofovir; Drug: Adefovir; Drug: Lamivudine
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Condition: Hepatitis B Infection
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Procedure: blood draw
Sponsor: Rockefeller University
Recruiting - verified March 2010
Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified March 2010
Conditions: Hemoglobinopathies; Hemolysis; Iron Deficiency and Overload; Anemias
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Conditions: Biliary Atresia; Cholestasis
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2010